Pharmacological therapy of neuroendocrine tumors

Tumori. 2010 Sep-Oct;96(5):847-57. doi: 10.1177/030089161009600538.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Algorithms
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Capecitabine
  • Chemotherapy, Adjuvant
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Digestive System Neoplasms / drug therapy*
  • Disease Progression
  • Drug Administration Schedule
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Gastrointestinal Agents / administration & dosage
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Interferon-alpha / administration & dosage
  • Intestinal Neoplasms / drug therapy
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / mortality
  • Neuroendocrine Tumors / pathology
  • Octreotide / administration & dosage
  • Octreotide / adverse effects
  • Octreotide / therapeutic use*
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Thoracic Neoplasms / drug therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Gastrointestinal Agents
  • Interferon-alpha
  • Organoplatinum Compounds
  • Oxaliplatin
  • Deoxycytidine
  • Capecitabine
  • Octreotide
  • Fluorouracil